Larimar’s FDA Breakthrough Designation for Ataxia Drug Includes Adult and Pediatric Patients

Key Facts

Larimar Therapeutics (Nasdaq: LRMR) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its lead drug candidate, nomlabofusp, for the treatment of Friedreich’s ataxia (FA). Crucially, the company confirmed that the designation covers both adult and pediatric patient populations, broadening the potential impact of the therapy. This regulatory status is designed to expedite the development and review of drugs intended to treat serious conditions. The FDA's decision was supported by clinical data and alignment on using skin frataxin (FXN) levels as a surrogate endpoint for accelerated approval. Larimar intends to submit a Biologics License Application (BLA) in June 2026, targeting a commercial launch in the U.S. during the first half of 2027. This milestone significantly de-risks the development process and enhances the company's path toward commercialization, serving as a positive catalyst for biotech investors.